Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02984813 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy
A Phase 1 study, sponsored by The New York Eye & Ear Infirmary.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02984813 is a Phase 1 study that was terminated before completion, run by The New York Eye & Ear Infirmary. The registered enrollment target is 21 participants.
The verdict
NCT02984813, a Phase 1 study, was terminated before completion, sponsored by The New York Eye & Ear Infirmary.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is a multi-armed protocol designed to evaluate the safety and efficacy of two different combinations of nutritional supplements (study drug) (Glauco-Health and Glauco-Select) chosen for their potential to protect retinal ganglion cells against oxidative stress, low-grade inflammation, and mitochondrial dysfunction in patients with open-angle glaucoma and diabetic retinopathy. Oxidative stress and retinal cellular dysfunction will be measured using a Retinal Metabolic Analyzer (RMA) in this randomized, single center, double masked study. Patients with glaucoma will be divided into three treatment arms randomized to receive either Glauco-Health, Glauco-Select, or placebo.
Interventions
- DRUG Placebo
- DRUG GlaucoHealth
- DRUG GlaucoSelect
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-04-15 |
| Est. Completion | 2017-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02984813
The ClinicalTrials.gov registry entry for NCT02984813 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The New York Eye & Ear Infirmary, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02984813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02984813 about?
NCT02984813 is a clinical study titled "Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy". This study is a multi-armed protocol designed to evaluate the safety and efficacy of two different combinations of nutritional supplements (study drug) (Glauco-Health and Glauco-Select) chosen for their potential to protect retinal ganglion cells against oxidative stress, low-grade inflammation, and...
What is the current status of trial NCT02984813?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-04-15. Estimated completion is 2017-01-15.
What interventions are being tested in trial NCT02984813?
The interventions under investigation include: Placebo (DRUG), GlaucoHealth (DRUG), GlaucoSelect (DRUG).
Who is sponsoring clinical trial NCT02984813?
This trial is sponsored by The New York Eye & Ear Infirmary, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.